NYHA Class Less Sensitive than KCCQ-OS for Capturing Heart Failure Progression


An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

This article was originally published on PracticalCardiology.com.

Heart failure diagnosis written on documents.

New research provides further evidence in favor of including patient-reported outcomes in the management of heart failure patients.

An analysis of patients from within the CHAMP-HF Registry, the 2872-patient study suggests patient-reported outcomes, as measured by the KCCQ-OS overall summary score, were more sensitive and better at tracking meaningful changes in health status over time when compared to use of NYHA class.

“Improvement in KCCQ-OS was independently associated with lower risk of subsequent mortality and the composite of mortality and HF hospitalization, whereas improvement in NYHA class was not associated with clinical outcomes,” wrote investigators.

With an interest in comparing the ability of the aforementioned scoring systems to characterize changes in disease state and their associations with clinical outcomes in HFrEF, the current study was designed by Stephen Greene, MD, of the Duke Clinical Research Institute, and a team of colleagues from multiple institutions, including Brigham and Women’s Hospital and University of Mississippi Medical Center. A prospective, noninterventional study inducted from December 2015-October 2017, the CHAMP-HF registry provided investigators with data related to more than 5000 patients with HF.

For inclusion in the current analysis, patients were required to have a diagnosis of chronic HF, a left ventricular ejection fraction of 40% or lower on most recent imaging within 12 months of enrollment, be receiving at least 1 oral medication at enrollment, and have completed data related to NYHA class and KCCQ-OS data at baseline and 12 months. Overall, 2872 patients met these criteria and were included in the study.

The median age of the study cohort was 68 years (IQR, 59-75 years), 30.4% were women, 75.1% identified as White, and the median ejection fraction was 30% (IQR, 23-35). Baseline assessments of NYHA class indicated 10.9% were NYHA class I, 59.5% were NYHA class II, 28.0% were NUHAclass III, and 1.6% were NYHA class IV. For KCCQ-OS, 39.4% scored between 75-100, 33.7% scored between 50-74, 21.3% scored between 25-49, and 5.6% of patients scored between 0-24.

At 12 months, 34.9% of patients had a change in NYHA, with 599 experiencing improvement and 403 experiencing a worsening score. For KCCQ-OS at 12 months, 2158 had a change of 5 or more, with 1388 experiencing an improvement and 26.8% experiencing a worsening score. Overall, the most common trajectory for KCCQ-OS was an improvement of 10 points or more (n=1047) and the most common trajectory of NYHA change was no change (n=1870).

In adjusted analyses, investigators found improvements in NYHA class were not associated with subsequent clinical outcomes, but an improvement of 5 or more points in KCCQ-OS was independently associated with decreased mortality (HR, 0.59; 95% CI, 0.44-0.80; P <.001) and mortality or hospitalization for worsening HF (HR, 0.73; 95% CI, 0.59-0.89; P=.002).

In an editorial comment, Paul Heidenreich, MD, MS, of the VA Palo Alto Health Care System, commended Greene and colleagues for their work and outlining the prognostic value of capturing RPO, but also noted real-world barriers to implementation need to be addressed to effectively implement capturing this data.

“The implication of the study by Greene et al is that the NYHA class should be reconsidered if it does not match the patient-reported data. When used together, prognosis assessment and treatment decisions will be improved,” wrote Heidenreich.

This study, “Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction,” was published in JAMA Cardiology.

Related Videos
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
Video 4 - "Innovations in Small Interfering RNA (siRNA) Therapy"
Video 3 - "Ongoing Lp(a) Trials and Clinical Approaches to Treatment"
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
© 2024 MJH Life Sciences

All rights reserved.